BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025)

BioNexus Gene Lab (BGLC) posted Share-based Compensation of $794770.0 for Q4 2025, up 983.07% sequentially from -$90001.0 in Q4 2023.

BioNexus Gene Lab (BGLC) Share-based Compensation (2023 - 2025) Analysis & Trends

BioNexus Gene Lab has reported Share-based Compensation for 2 years, with the latest figure at $794770.0 in Q4 2025.

Quarterly Share-based Compensation changed N/A year-over-year to $794770.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $704769.0 (changed N/A YoY) and the FY2025 annual result came in at $794770.0, up 463.67% from the prior year.
Share-based Compensation rose to $794770.0 in Q4 2025 per BGLC's latest filing, from -$90001.0 in the prior quarter.
Over five years, Share-based Compensation peaked at $794770.0 in Q4 2025 and troughed at -$90001.0 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Stock Comp. (Qtr)
1	Linde	226.70 Bn	221.80 Bn	4.43 Bn	19.00 Mn
2	Sherwin Williams	85.01 Bn	84.72 Bn	3.34 Bn	27.80 Mn
3	Ecolab	79.30 Bn	74.17 Bn	1.95 Bn	-
4	Air Products & Chemicals	68.39 Bn	67.41 Bn	1.04 Bn	12.20 Mn
5	Ppg Industries	25.34 Bn	23.74 Bn	1.81 Bn	16.00 Mn
6	Chemical & Mining Co Of Chile	23.49 Bn	19.63 Bn	778.60 Mn	-
7	LyondellBasell Industries	22.25 Bn	19.62 Bn	2.04 Bn	19.00 Mn
8	International Flavors & Fragrances	21.58 Bn	21.01 Bn	853.00 Mn	35.00 Mn
9	DuPont de Nemours	19.01 Bn	17.27 Bn	639.00 Mn	11.00 Mn
10	BioNexus Gene Lab	2.43 Mn	-1.10 Mn	12,982.00	-

Download Data